Aktuellt
SENASTE
IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in its Phase IIb study investigating mesdopetam in the treatment of patients with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). We see this as a significant milestone for the trial as IRLAB now looks to complete the data package following completion of the treatment period and to report top-line results in mid-January 2023. We had previously communicated that initial top-line readouts from the study would be disclosed around Q422. However, we do not see this as having any major impact on mesdopetam’s developmental timeline in PD-LIDs. We value IRLAB at SEK6.72bn or SEK129.8 per share.
LÄS MER
